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Objective: Ischemia–reperfusion injury continues to plague the field of lung transplantation, resulting in subop-
timal outcomes. In acute lung injury, processes such as ventilator-induced injury, sepsis, or acute respiratory dis-
tress syndrome, extravascular fibrin has been shown to promote lung dysfunction and the acute inflammatory
response. This study investigates the role of the fibrinolytic cascade in lung ischemia–reperfusion injury and
investigates the interplay between the fibrinolytic system and the inflammatory response.
Methods: Mice lacking the plasminogen activator inhibitor-1 gene (PAI-1 knock out, PAI-1 KO; and thus
increased lysis of endogenous fibrin) and wild-type mice underwent in situ left lung ischemia and reperfusion.
Fibrin content in the lung was evaluated by immunoblotting. Reperfusion injury was assessed by histologic
and physiologic parameters. Proinflammatory mediators were measured in bronchoalveolar lavage fluid and
plasma using enzyme-linked immunosorbent assays.
Results: Ischemia–reperfusion causes fibrin deposition in murine lungs. Less fibrin was seen in PAI-1 KO mice
than in wild-type mice subjected to the same ischemia–reperfusion conditions. By histologic criteria, more
evidence of ischemia–reperfusion injury was noted (thickening of the interstium, cellular infiltration in the
alveoli) in the wild-type than in PAI-1 KO mice. Physiologic parameters also revealed more ischemia–reperfusion
injury in the wild-type than in PAI-1 KO mice. Cytokine and chemokines were elevated more in the wild-type
group than the PAI-1 KO group.
Conclusions: Lung ischemia–reperfusion injury triggers fibrin deposition in the murine lungs and fibrin creates
a proinflammatory environment. Preventing fibrin deposition may reduce ischemia–reperfusion injury and in-
flammation. This finding may lead to novel treatment strategies for ischemia–reperfusion.
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XLung transplantation currently is the preferred treatment op-
tion for a variety of end-stage pulmonary diseases. Remark-
able progress has occurred through refinement in technique
and improved understanding of transplant immunology and
microbiology. Despite improvements in preservation, ische-
mia–reperfusion injury (IRI) continues to result in unpredict-
able suboptimal outcomes in lung transplant recipients. The
incidence of IRI ranges from 10% to 25% in most series,1,2
and there is mounting evidence that IRI is associated with
an increased risk for the development of bronchiolitis
obliterans.3,4
IRI is a form of acute lung injury. It is widely documented
that increased coagulation and impaired fibrinolysis play an
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acute lung injury.5 Extravascular fibrin deposition has
been shown to promote lung dysfunction, and furthermore
intravascular thrombosis occurs in the acutely injured
lung.6 Depression of fibrinolysis has been shown to increase
detection of fibrin, and this results mostly through amplifica-
tion of plasminogen activator inhibitor-1 (PAI-1), which is
a 52-kDa serine protease inhibitor that serves as the major
plasma inhibitor of tissue-type plasminogen activator and
urokinase-type plasminogen activator. Hypoxia has been
shown also to increase PAI-1 and promote pulmonary vas-
cular fibrin deposition.7 Figure 1 details the fibrinoltyic/
PAI-1 pathway.
An important area of recent interest has been the interplay
between coagulation and inflammation in acute lung injury,
and much has been written on this topic in acute lung injury
from adult respiratory distress syndrome, sepsis, and ventila-
tor-induced lung injury.5 One concept that has emerged over
the past decade is that coagulation and inflammation are
linked and should not be considered different distinct path-
ways.5 Anticoagulants reduce inflammation and result in im-
proved outcomes in animal models of sepsis and acute lung
injury.5 Tissue fibrin is known to influence local alveolar in-
flammation in a variety of ways.6 Therefore, fibrinolysis may
be useful for preventing inflammation during lung IRI.
This article examines the role of changes in the fibrino-
lytic pathway in IRI by using PAI-1 knock-out (KO) micerdiovascular Surgery c Volume 137, Number 5 1241
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XAbbreviations and Acronyms
BAL ¼ bronchoalveolar lavage
ELISA ¼ enzyme-linked immunosorbent assay
IR ¼ ischemia–reperfusion
IRI ¼ ischemia–reperfusion injury
KC ¼ keratinocyte chemoattractant
KO ¼ knock out
IL-10 ¼ interleukin 10
MCP-1 ¼ monocyte chemoattractant protein-1
MIP-2 ¼ macrophage inflammatory protein-2
PAI-1 ¼ plasminogen activator inhibitor-1
PCR ¼ polymerase chain reaction
PE ¼ polyethylene
RT-qPCR ¼ real-time quantitative polymerase
chain reaction
TNF-a ¼ tumor necrosis factor-alpha
WT ¼ wild type
in our mouse ischemia–reperfusion (IR) model. We try to
investigate the association between fibrin deposition and
the inflammatory response in our experimental model. We
hypothesize that enhancing fibrin turnover will decrease




C57BL6 (wild-type; WT) and PAI-1 knock-out (PAI-1 KO; also on
a C57BL6 background) male mice (Jackson Laboratory, Bar Harbor,
Maine) (28–35 g) were used for all studies and received humane care in ac-
cordance with the ‘‘Principles of Laboratory Animal Care,’’ formulated by
the National Society for Medical Research, and the ‘‘Guide for the Care and
Use of Laboratory Animals’’ prepared by the National Academy of Sci-
ences and published by the National Institutes of Health. The study protocol
was reviewed and approved by the Animal Care and Use Committee at the
University of Virginia before experimentation.
Experimental Protocol of IR
Three experimental groups (WT-sham, WT-IR, and PAI-1 KO IR) were
compared using an in vivo left hilar clamp model. WT-IR and PAI-1 KO IR
groups underwent 1 hour of left hilar clamping followed by 2 hours of reper-
fusion at room temperature. The WT-sham group underwent chest opening
and closure but no hilar clamping. A minimum of 6 mouse lungs were studied
per group (6 mice with 1 lung each). In this model of IR lung injury, mice are
anesthetized with inhalational isoflurane, intubated, connected to a volume-
controlled ventilator (Harvard Apparatus Co, South Natick, Mass), and ven-
tilated with room air. Heparin (30 U/kg) is given via injection into the right
external jugular vein. The left hilum is approached via a left thoracotomy.
The left fourth rib is cut with a cautery pen at about 2 mm lateral to the ster-
num. A 6–0 Prolene polypropylene suture (Ethicon, Inc, Somerville, NJ) is
placed around the left hilum and both ends are threaded out through a piece of
polyethylene (PE)-10 tubing. The left hilum is occluded by pushing down the
PE tubing while pulling tension on the suture. A small surgical clip is placed
around the suture to keep the PE tubing in position. The left lung is rendered
ischemic for 1 hour; reperfusion is then established by removing the PE tub-
ing and the suture. The wound is suture-closed in layers. The mouse is al-1242 The Journal of Thoracic and Cardiovascular Sulowed to awaken and recover in the cage. The WT-sham operated controls
were subjected to the same perioperative protocols as the mice (ie, sedation,
hydration, warming mattress); a left thoracotomy was performed with dissec-
tion of the hilum and then left thoracotomy site was closed.
In Situ Buffer-Perfused Mouse Lung Model
(to Obtain Physiologic Parameters)
After 2 hours of reperfusion, one group of the mice in each set of exper-
iments was reanesthetized and pulmonary function evaluated by an in situ
buffer-perfused mouse lung system. The isolated perfused mouse lung sys-
tem (Hugo Sachs Elektronik–Harvard Apparatus GmbH, March-Hugstet-
ten, Germany) was used as previously described by our laboratory.8 An
advantage of this system is that the lungs are not removed from the chest
cavity, but instead the whole animal is placed in the chamber with an
open chest. In brief, the animal is anesthetized (pentobarbital sodium, 160
mg/kg, intraperitoneally) and placed on the heated operating table, and a tra-
cheotomy is performed. The skin is incised in a median line from the abdo-
men to the neck. Positive-pressure ventilation is initiated at 120 breaths/min
before the thorax is opened, and ventilation pressure is controlled so that
a tidal volume of approximately 15 mL/kg is achieved with a positive
end-expiratory pressure of 2 cm H2O. The abdominal wall is incised and
the incision extended laterally on both sides to the lower extremities so
that the vessels of the thigh become visible and accessible. The diaphragm
is carefully removed and the thorax is opened by median sternotomy. The
animals are exsanguinated by a cut through the renal vein 30 seconds after
injection of 50 units of heparin. Krebs–Henseleit buffer that contains 2%
albumin, 0.1% glucose, and 0.3% HEPES is used for perfusing the lungs.
The Krebs solution is prepared to mimic right ventricular blood (mixed ve-
nous blood) using a gas bubbling stone with titrated gases generating a pH
of 7.40 to 7.45, a PO2 of 60 to 70 mm Hg, and a PCO2 of 50 to 60 mm Hg. The
buffered perfusate and isolated lung apparatus are maintained at 37C. With
the use of an operating microscope, the thymus is dissected cephalad expos-
ing the great vessels. The pulmonary artery and left atrium are cannulated,
and the perfusate flow is set to a final perfusion rate of 2 mL/min. The left
ventricle is vented with a small incision at the apex of the heart. The mitral
apparatus is carefully dilated and the left atrial cannula is passed through the
mitral valve and into the left atrium. The placement of the pulmonary artery
and left atrial cannulas is further confirmed by a pressure tracing generated
FIGURE 1. The fibrinolytic system. This system is strictly regulated by
plasminogen activators, plasminogen activator receptor, plasminogen acti-
vator inhibitors, and a2-antiplasmin.rgery c May 2009
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Xby the Pulmodyn data acquisition system (Hugo Sachs Elekrtonik). Lungs
are allowed to equilibrate for a 10-minute stabilization period. The follow-
ing parameters are measured and stored using the computer data acquisition
software: (1) pulmonary compliance, (2) pulmonary artery pressure, and (3)
airway resistance.
Western Blot
For these experiments, each mouse was injected with 20 units of heparin
before being humanely killed. Immediately after harvest, the mouse’s left
lung was placed in ice-cold homogenizing buffer (20 mmol/L Tris, 100
mmol/L NaCl, and 2.7 mg/mL heparin) and then homogenized by six 10-
second rounds of homogenization. Tissue extracts were incubated with
0.32-unit of human plasmin (Sigma Chemical Co, St Louis, Mo) at 37C
for total 8 hours on a rotating shaker. After centrifugation, collected super-
natants were transferred to a fresh tube and stored at80C for analysis. The
solubilized protein was then loaded onto a sodium dodecylsulfate–poly-
acrylamide gel for electrophoresis after the concentration of total protein
was adjusted. Transferred membranes were blocked with 5% nonfat skim
milk for 2 hours and incubated with murine monoclonal antibody against
fibrin (American Diagnostic, Stamford, Conn) for 16 hours at4C. After
being washed three times with Tris-buffered saline with 0.05% Tween
20, the membranes were incubated with peroxidase-conjugated secondary
antibody for 2 hours. The membrane was washed three times with Tris-buff-
ered saline and developed using Amersham ECL Western blotting detection
reagents (GE Healthcare, Buckinghamshire, United Kingdom).
Histology
Whole-lung tissue specimens were immediately fixed in 10% formalin.
After 24 hours they were embedded in paraffin and then cut and stained with
hematoxylin and eosin or stained by immunohistochemistry.
Immunohistochemical staining. The experiments were per-
formed as described previously.9,10 A rat anti-mouse neutrophils antibody
(AbD Serotec, Raleigh, NC) and a rat anti-mouse macrophage antibody
(Mac-2, Accurate Chem, Westbury, NY) were used as primary antibodies.
Alkaline phosphatase–conjugated anti-rat immunoglobulin G (Sigma) was
used as secondary antibody. The signals were detected with Fast-Red
(Sigma). Purified normal rat immunoglobulin G (eBioscience Inc, San
Diego, Calif) was used as negative controls. The sections were counter-
stained lightly with hematoxylin for viewing negatively stained cells. The
number of neutrophils and macrophages per high-power field was assessed
via immunohistochemical staining of peripheral lung sections. Six fields
were counted per lung. Three individuals who count the positive stained
cells were blinded to the condition being assessed. The average cell number
was used for statistic analysis.
Plasma. The mice for blood withdrawing in this experiment were not
used for obtaining physiologic parameters using the in situ buffer-perfused
mouse lung model. After the animal was humanely killed, the blood was
collected by left arterial puncture (approximately 0.80–1 mL per mouse)
into tubes containing 50 uL of 169 mmol/L ethylenediaminetetraacetic
acid. Plasma was collected by centrifugation (15003g, 5 minutes) and
stored at80C for later cytokine analyses.
Bronchoalveolar lavage (BAL) fluid collection. BAL fluid
was collected by washing with 2 separate aliquots of 1 mLof Ca2þ- and
Mg2þ-free Hanks balanced salt solution (Gibco BRL, Life Technologies,
Inc, Grand Island, NY) through the trachea. The first wash was centrifuged
and the BAL supernatant stored for cytokine and chemokine analysis. The
second wash was centrifuged, and the cell pellet from the first wash was
pooled with the cell pellet from the second.
Cytokine and chemokine analysis. Monocyte chemoattractant
protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-a), keratinocyte che-
moattractant (KC), and macrophage inflammatory protein-2 (MIP-2) were
chosen to be measured. All chemokine and cytokine measurements were
performed simultaneously to reduce errors because of interassay variation.The Journal of Thoracic and CMCP-1, TNF-a, and KC were measured by enzyme-linked immunosorbent
assay (ELISA) using matched antibody pairs (R&D System, Inc, Minneap-
olis, Minn) as previously described11 For lung homogenates, the left lungs
were removed and immediately placed in 3.0 mL ice-cold homogenization
buffer (1 tablet of protease inhibitor cocktail; Complete Roche, Penzberg,
Germany) with 0.05% Triton X-100 (Sigma) in 50 mL phosphate-buffered
saline solution). Three 10-second rounds of homogenization and sonication
were followed by centrifugation (15,0003g for 15 minutes at 4C). The su-
pernatants were removed and stored at80C for later cytokine/chemokine
assay. Addtionally, total RNA was extracted from the left lung by Trizol
according to manufacturer protocols (Invitrogen Corporation, Carlsbad,
Calif). Real-time quantitative polymerase chain reaction (RT-qPCR) was
carried out using TaqMan probe-based chemistry (Applied Biosystems,
Carlsbad, Calif) according to a previous report.12 The primers and probe
were designed against GenBank-published sequences in association with
Primer Express (Applied Biosystems).
Data Analysis
Statistical differences between results were determined by 1-way analy-
sis of variance followed by the Tukey multiple comparison test for the com-
parison of more than two categorical variables or by the t test for two group
comparison. Data were represented as the mean  standard error from six
separate experiments.
RESULTS
We used mice null for PAI-1 (which would potentially de-
crease the net accrual of fibrin during IR) in a series of IR
experiments and compared these with WT-IR mice. As
can be seen in Figure 2, real-time PCR showed that PAI-1
mRNA was not present in the left lung of PAI-1 KO mice,
whereas abundant PAI-1 mRNA was present in that of
WT-C57BL/6 mice (Figure 2, A). Western analysis of lung
tissue after IRI demonstrated fibrin deposition in the WT
mice lungs and less deposition of fibrin in the PAI-1 KO
mice (Figure 2, B). These studies suggest that deletion of
PAI-1 enhances fibrinolysis under conditions of IR. Inas-
much as these immunoblots were performed on entire lung
FIGURE 2. Expression of PAI-1 and fibrin in the WT mice and PAI-1 KO
mice. A, Expression of PAI-1 mRNA in WT and PAI-1 KO left lung as de-
termined by real-time PCR. b-actin was used to normalize the PAI-1 mRNA
expression. B, Western blot analysis of fibrin expression in the lung from
WT-IR and PAI-1 KO IR mice. Fibrin concentration is substantially reduced
in PAI-1 KO mice compared with WT mice.ardiovascular Surgery c Volume 137, Number 5 1243
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XFIGURE 3. Immunohistochemical staining of neutrophils and macrophages in mice lung. Cells stained red indicate neutrophils or migratory macrophage
infiltration. All sections were counterstained lightly with hematoxylin for viewing negatively stained cells. A, D, and G are stained with anti-Mac-2 antibody,
B, E, and H are stained with antineutrophils antibody and C, F, and I are stained with normal rat immunoglobulin G (IgG).All figures are 2003magnifications.
The bar graph shows the analysis of positive immunostaining of neutrophils and macrophages in the left lung of sham, WT-IR, and PAI-1 KO IR groups. Data
shown are the mean  standard error values for each group.1244 The Journal of Thoracic and Cardiovascular Surgery c May 2009
Lau et al Cardiothoracic TransplantationFIGURE 4. Pulmonary compliance, pulmonary artery pressures, and airway resistance in the PAI-1 KO IR mice compared with the WT-IR and sham mice.
These physiologic parameters show less IRI in the PAI-1 KO IR compared to WT-IR. A, Comparison of lung compliance in sham, PAI-1 KO IR, and WT-IR
mice. B, Comparison of pulmonary artery (PA) pressure in sham, PAI-1 KO IR, and WT-IR mice. C, Comparison of airway resistance in sham, PAI-1 KO IR
and WT-IR mice. Data shown are the mean  standard error values for each group. All P values are included in graph.T
Xextractions, we cannot determine from these experiments
which compartment (intra-alveolar, intravascular, or extra-
vascular) accounted for the decrease in fibrin deposition in
PAI-1 KO mice. Additionally, it could be a combination
of compartments.
Histology and Immunohistochemistry
The histologic samples of the left lung of WT-sham, WT-
IR, and PAI-1 KO IR mice are shown in Figure 3. The inter-
stitium of the left lung in WT-IR and PAI-1 KO IR mice
appeared thicker with more cellularity and edema than that
of sham mice. The WT-IR mice had the most pronounced
IRI. Immunohistochemical staining revealed that more neu-
trophil and macrophage infiltration was seen in the left lung
of WT-IR compared with the PAI-1 KO IR and WT-sham
mice. These results indicate that the plasminogen activa-
tor/PAI-1 system may play an important role in recruitment
of inflammatory cells during lung transplantation.
Physiologic Data
As shown in Figure 4, there was a significant protection in
pulmonary compliance, pulmonary artery pressures, and air-The Journal of Thoracic and Cway resistance in the PAI-1 KO IR mice compared with the
WT-IR mice. The mean pulmonary compliance in the WT-
sham group was 5.587 0.547 mL/cm H2O; this was not sta-
tistically different from the mean compliance in the PAI-1
KO IR group, which was 4.292  0.377 mL/cm H2O (P ¼
.08). These values were markedly better than the mean com-
pliance, 2.552  0.202 mL/cm H2O, in the WT-IR mice
lungs (P ¼.003). The mean pulmonary artery pressures
were markedly higher in the WT-IR mice, 12.53 cm H2O,
compared with both PAI-1 KO IR (9.23 cm H2O) and
WT-sham mice (5.70 cm H2O) (P< .0001). In terms of air-
way resistance, the WT-IR was also significant worse, 2.240
 0.287 cm H2O/mL/s, compared with PAI-1 KO IR (1.240
 0.114 cm H2O/mL/s) and sham-IR (0.788  0.038 cm
H2O/mL/s). Unlike pulmonary compliance, in which there
was no significant difference between PAI-1 KO IR and
sham-IR, the protection compared with WT-IR was only
partial. Pulmonary artery pressure and airway resistance
with PAI-1 KO IR had higher pulmonary artery pressures
and airway resistance compared with sham-IR (P< .0001
and P ¼ .004, respectively). Taken together, these data
show the IRI in PAI-1 KO IR mice was less when comparedardiovascular Surgery c Volume 137, Number 5 1245
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XFIGURE 5. Proinflammatory mediators in plasma and BAL of IR injured mice. A, ELISA analysis showing TNF-a and MCP-1 in the plasma of WT-IR and
PAI-1 KO IR mice. B, ELISA analysis showing TNF-a, KC, and MIP-2 in BAL of WT-IR and PAI-1 KO IR mice. C, Analysis showing mRNA expression of
TNF-a, MCP-1, MIP-2, and KC in the left lung of WT and PAI-1 KO mice as determined by real-time PCR. Data shown are the mean standard error values
for each group.with that in WT-IR mice, although there was still evidence of
some injury. These data corroborate the histology and im-
munohistochemisty data.
Chemokine/Cytokine Data
TNF-a in plasma samples was significantly lower in the
PAI-1 KO IR mice (0.136  0.007 ng/mL) than in the
WT-IR mice (0.270  0.054 ng/mL; P ¼ .027). MCP-1 in
plasma samples was also significantly lower in the PAI-1
KO IR (0.026  0.0002 ng/mL) than in WT-IR mice
(0.039  0.005 ng/mL; P ¼.017). MIP-2 trended lower in
plasma samples in the PAI-1 KO IR mice than in the WT-
IR mice, but this did not reach statistical significance (P ¼
.190). However, in all the PAI-1 KO IR mice, MIP-2 levels
were below detection limit of the ELISA. In the WT-IR
mice, MIP-2 levels were detectable (0.604  0.373 ng/
mL) (see Figure 5, A). KC levels were below the detection1246 The Journal of Thoracic and Cardiovascular Sulimits in the plasma samples in both groups. In BAL sam-
ples, TNF-a, KC, and MIP-2 were significantly lower in
the PAI-1 KO IR group (0.003  0.0002 ng/mL, 0.007 
0.016 ng/mL, and 0.029  0.004 ng/mL, respectively)
than in the WT-IR group (0.005  0.0006 ng/mL, 0.019
 0.002 ng/mL, and 0.078  0.0197 ng/mL; respectively)
(P ¼ .003, .0006, and .027, respectively) (see Figure 5, B).
MCP-1 levels in the BAL were below detection limits in
both groups. Taken together, these data suggest that local ab-
normalities of fibrinolysis in IR affect the various inflamma-
tory cytokines/chemokines locally, and these effects may
also be reflected in the systemic circulation. We also per-
formed ELISAs on whole lung homogenates as well as ex-
tracted total RNA from the left lung for real-time PCR,
and there did not appear to be a significant different in any
of the measured cytokines/chemokines (Figure 5, C) which
suggests the intra-alveolar inflammatory component may be
most affected locally.rgery c May 2009
Lau et al Cardiothoracic Transplantation
T
XDISCUSSION
A substantial body of evidence supports the idea that co-
agulation, fibrinolysis, and extravascular fibrin deposition
play a role in acute lung injury and subsequent repair.6 De-
position of alveolar fibrin is characteristic of a wide range of
acute insults in lung models. In the acutely injured lung, in-
travascular thrombosis can also occur. Extravascular fibrin
deposition promotes an acute inflammatory response and
lung dysfunction.6 Alveolar deposition is also characteristic
of diffuse alveolar damage that occurs from various insults.6
Evidence supports transitional fibrin neomatrix involved in
pathogenesis of acute inflammatory response in acute lung
injury.
We have previously investigated the effects of hypoxia on
the fibrinolytic system.7 Mice exposed to hypoxia were
found to have an increase in plasma levels of PAI-1 and a de-
crease in tissue-type plasminogen activator and urokinase-
type plasminogen activator. The co-localization studies
with immunohistochemistry identified macrophages as the
predominant source of increased PAI-1 within the hypoxic
lung.7
In our IRI model, we found decreased deposition of fibrin
in the PAI-1 KO IR mice and a protective effect on injury in
these mice. We do not know from these studies in which
compartment(s) of the lung (intravascular, interstitium or in-
tra-alveolar) the decrease in fibrin is seen, but it does appear
that with this decrease in fibrin there is a decrease in inflam-
mation. We have previously reported on the interplay be-
tween the fibrinolytic system and inflammation in IRI.
After IR interleukin 10 (IL-10), null mice (IL-10 suppresses
macrophage activation and downregulates proinflammatory
cytokine production) were found to have exaggerated pul-
monary PAI-1 expression compared with mice with IL-10.
These mice null for IL-10 showed poor postischemic func-
tion and survival compared with mice with IL-10.13 Further-
more, in this study, recombinant IL-10, when given to mice
null for IL-10 normalized the PAI/tissue-type plasminogen
activator ratio, reduced pulmonary vascular fibrin deposition
and rescued mice from lung injury.13
Farivar and colleagues14 have also reported on the cross-
talk between thrombosis and inflammation in a rat lung re-
perfusion injury model. In this article they used a specific
direct thrombin inhibitor, hirudin, and showed that it pro-
tected against IRI. They also suggested mechanistically
that the protective effects of thrombin inhibition were a result
of decreased inflammatory pathway activation. Thrombin
exerts proinflammatory influences on neutrophils, endothe-
lial cells, and macrophages, and thus inhibition of thrombin
with hirudin prevents this proinflammatory activation.
Our current findings are additive to our previous studies
and those of Farivar and colleagues. The PAI-1 KO mice
prevent fibrin accrual in the lung by increasing fibrinolysis.
We saw less of an inflammatory response with less neutro-The Journal of Thoracic and Caphil infiltration, less cytokine and chemokine release, and
improvement in physiologic parameters with the PAI-1
KO mice compared with controls.
The importance of PAI-1 in clinical lung transplantation
is suggested by a study performed by Christie and col-
leagues.15 They found higher PAI-1 levels in plasma of
human lung transplant recipients with severe IRI than in
plasma of patients without IRI. This increase in plasma
PAI-1 levels has also been seen in patients with adult respi-
ratory distress syndrome compared with critically ill control
patients.16
The transitional fibrin that is found at the time of acute
lung injury has been linked to various pulmonary fibrotic
conditions.6 Not only does tissue fibrin influence inflam-
mation, it also affects tissue repair responses. The presence
and severity of IRI is a major risk factor in the develop-
ment of chronic allograft rejection.3,4 Chronic allograft re-
jection in the lung is a fibro-obliterative process of the
small airways. Although this study does not investigate
the role played by fibrin deposition in the subsequent
development of chronic allograft lung rejection, it does
suggest that one way IRI may increase the risk of develop-
ment of chronic rejection is via alterations in the fibrino-
lytic system.
The current study focuses on impaired fibrinolysis. The
protection seen with the PAI-1 KO mice was only partial
but significant in our studies. We plan future studies to
look at whether increased coagulation also contributes to
IRI. In human lung transplant recipients that have severe
IRI, evidence of enhanced coagulation is seen by decreased
levels of protein C.15
In summary, our study provides evidence to support the
hypotheses that PAI-1 plays an important role during lung
IRI via (1) decreasing fibrin deposition, (2) suppressing
cytokine/chemokines involved in inflammation and
chemotaxis, and (3) blocking inflammatory cells (such as
neutrophil and macrophage) infiltration into the injured
lung tissues. Our data indicate that the association between
fibrinolysis and inflammation in our lung IRI model may
provide potential novel therapeutic targets for lung trans-
plantation. For example, treatment with angiotensin-con-
verting enzyme inhibitors quinapril (40 mg) and ramipril
(10 mg) have been reported to decrease plasma PAI-1 anti-
gen and PAI-1 activity significantly, but without affecting
the level and activity of tissue plasminogen activator in
patients.17,18 Therefore, angiotensin-converting enzyme
inhibitors could be administered to the donor to enhance fi-
brinolysis when heparin is given already as a routine before
cold flush perfusion to prevent thrombosis. We will further
investigate whether this early stage protection will attenuate
bronchiolitis obliterans development during late stages of
lung transplantation using our heterotopic tracheal trans-
plantation model.rdiovascular Surgery c Volume 137, Number 5 1247
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